Akers Biosciences, Inc. Temporary Suspension of Share Trading on LSE (7047G)

TIDMAKR

RNS Number : 7047G

Akers Biosciences, Inc.

08 November 2018

November 8, 2018

Akers Biosciences, Inc.

Temporary Suspension of Share Trading on London Stock Exchange

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces a temporary suspension of trading in the Company's shares on the AIM market of the London Stock Exchange, with effect from 7.30 a.m. GMT on November 8, 2018.

On November 7, 2018, the Company announced a reverse stock split of its issued and oustanding common stock of no par value. The reverse stock split is expected to become effective on November 8, 2018, with consolidated common shares trading on the Nasdaq Capital Market with effect from November 8, 2018. The Company is completing the necessary work streams for admission to AIM of the consolidated common shares. This work is expected to take approximately five to seven business days to complete. The Company's shares will remain suspended from trading on AIM until this work is complete.

A further announcement will be made in due course.

This announcement has no effect on the trading of the Company's shares on Nasdaq Capital Market, which continues as normal.

Inquiries:

Akers Biosciences, Inc.

Howard R. Yeaton, Chief Executive Officer and Interim Chief Financial Officer

Tel. [phone]

finnCap (UK Nominated Adviser and Broker)

Ed Frisby / Scott Mathieson (Corporate Finance)

Tel. [phone]

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. [phone]

Email: [e-mail]

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com.

Cautionary Note Regarding Forward-Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, compliance with the requirements of various regulatory agencies and certain NASDAQ Stock Market listing rules, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should, " "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

SUSUBVARWVAARUA

(END) Dow Jones Newswires

November 08, 2018 02:00 ET (07:00 GMT)